Key result
Pre-ablation dabigatran interruption shows comparable safety to uninterrupted warfarin in AF ablation.
Why the study?
The safety profile of cessation of dabigatran therapy 4 days before atrial fibrillation ablation compared to uninterrupted warfarin therapy was unclear.
Does cessation of dabigatran therapy 4 days pre AF ablation have a comparable safety profile to uninterrupted warfarin therapy in patients undergoing atrial fibrillation ablation?
Cohort
Does cessation of dabigatran therapy 4 days pre AF ablation have a comparable safety profile to uninterrupted warfarin therapy in patients undergoing atrial fibrillation ablation?
Absolute Event Rate: 2.4% vs 2%
p-value: p=0.83
Cessation of dabigatran therapy 4 days prior to atrial fibrillation ablation has a comparable safety profile to uninterrupted warfarin therapy.
Should not yet alter periprocedural anticoagulation protocols; leaves open need for randomized confirmation in AF ablation.
VASc and HASBLED scores and greater prevalence of aortic plaque. The major complication rate was 2.0% in the warfarin group and 2.4% in the dabigatran group (P= 0.83). The minor complication rate was 2.5% in the warfarin group and <1% in the dabigatran group (P= 0.27). In the dabigatran group, there was one renal thromboembolic event 4 days post-ablation. All patients in the warfarin group who suffered a major complication required a blood transfusion. Cessation of dabigatran therapy 4 days pre AF ablation has a comparable safety profile to uninterrupted warfarin therapy.
No takes yet. Share an insight, caveat, or question.
García et al. (2014) conducted a cohort in Atrial Fibrillation Ablation. Dabigatran (cessation 4 days pre-ablation) vs. Uninterrupted warfarin therapy was evaluated on Major complication rate (p=0.83). Cessation of dabigatran therapy 4 days prior to atrial fibrillation ablation showed a comparable safety profile to uninterrupted warfarin, with major complication rates of 2.4% vs 2.0% (P=0.83).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: